Abstract
Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease. This study investigated the effect of multiple daily oral doses of omeprazole on the pharmacokinetics, safety, and tolerability of a single oral dose of roxadustat. This phase 1, open-label, two-period, one-sequence, crossover study enrolled healthy subjects. During Period 1, subjects received a single oral dose of 100 mg roxadustat. After a ≥ 7-day washout, subjects started Period 2 and received daily oral doses of 40 mg omeprazole on Days 1-9, and a single oral dose of 100 mg roxadustat on Day 7. Roxadustat pharmacokinetics were assessed on Days 1-4 in Period 1 and on Days 7-10 in Period 2. Primary endpoints were area under the concentration-time profile from the time of dosing extrapolated to infinity (AUCinf) and maximum concentration (Cmax). Safety was assessed by vital signs, laboratory tests, electrocardiograms, and nature, frequency, and severity of treatment-emergent adverse events (TEAEs). Eighteen subjects were enrolled. The geometric least squares mean ratio for both AUCinf and Cmax of roxadustat (with omeprazole/alone) was 104.5%; 90% confidence intervals were within the no-eff...Continue Reading
References
Jan 1, 1985·Gastroenterology·P J PrichardW J Louis
Dec 17, 1997·Digestive Diseases and Sciences·K H GanH G Heijerman
Mar 10, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Karl Broich, UNKNOWN Committee for Medicinal Products for Human Use
Sep 1, 2012·Journal of the American Society of Nephrology : JASN·Jodie L Babitt, Herbert Y Lin
Jan 7, 2014·PloS One·Melissa E Stauffer, Tao Fan
Jun 25, 2015·Medicine·Katherine GarloMark G Parker
Aug 5, 2015·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Anatole BesarabThomas B Neff
Oct 24, 2015·Journal of the American Society of Nephrology : JASN·Anatole BesarabThomas B Neff
Feb 6, 2016·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Robert ProvenzanoThomas B Neff
Mar 8, 2016·Clinical Therapeutics·Dorien Groenendaal-van de MeentMarloes Schaddelee
Apr 21, 2016·Clinical Journal of the American Society of Nephrology : CJASN·Robert ProvenzanoThomas B Neff
May 6, 2016·Expert Opinion on Drug Safety·Lucia Del Vecchio, Francesco Locatelli
Jun 17, 2016·Medicine·Ya LiNan Chen
Jun 29, 2016·Clinical Drug Investigation·Dorien Groenendaal-van de MeentMarloes Schaddelee
Jul 28, 2016·BMC Nephrology·Daniel ErikssonFloortje van Nooten
Jan 25, 2017·American Journal of Nephrology·Francesco LocatelliIain C Macdougall
Mar 1, 2017·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Nupur Gupta, Jay B Wish
Apr 4, 2017·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Nan ChenFrank H Valone
Jun 5, 2017·Advances in Therapy·Adrian CovicDimitrie Siriopol
Citations
Feb 26, 2019·Drugs·Sohita Dhillon
Dec 5, 2019·International Journal of Molecular Sciences·Wei-Ting ChangSheng-Nan Wu
Nov 10, 2020·European Journal of Drug Metabolism and Pharmacokinetics·Dorien Groenendaal-van de MeentMartin den Adel
Jan 25, 2021·Clinical Pharmacokinetics·Dinko RekićBengt Hamrén
May 8, 2020·Drug Discovery Today·Kaijun SuXiaojin Zhang
Sep 4, 2019·Advances in Chronic Kidney Disease·Neil S Sanghani, Volker H Haase
Mar 30, 2021·Kidney International Supplements·Volker H Haase